NICE recommends Janssen’s Darzalex myeloma combo

pharmafile | March 12, 2019 | News story | Manufacturing and Production Janssen, NICE, Velcade, darzalex, myeloma 

Britain’s cost effectiveness body NICE have recommended Janssen Pharmaceutical’s Darzalex in combination with Velcade and dexamethasone (DVd), for use within the cancer drugs fund as an option for treating relapsed multiple myeloma in people who have had one previous treatment.

In recommending the treatment NICE agreed that the drug combo was “clinically important and statistically significant effect on progression-free survival.” However the government body stopped short of making the treatment routinely available as they argued that data to back up its survival benefit in the long-term is limited.

The drug will be offered through the Cancer Drugs Fund and will thus be available to patients. However Janssen commented in suggesting it was disappointed that routine access was not being offered on the NHS.

Jennifer Lee, director of health economics, market access and reimbursement (HEMAR) and advocacy at Janssen, commented: “While it is positive news that patients will now be able to access DVd, it is disappointing that NICE – despite recognising the life-extending, step-change this combination represents for patients – did not recommend routine access on the NHS. The parameters through which NICE determines uncertainty need urgent re-evaluation.”

Louis Goss

Related Content

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …


Janssen submits sNDA to FDA for full approval of Balversa

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …

Amicus Therapeutics’ Pompe disease treatment approved for use in UK

Amicus Therapeutics has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the …

Latest content